Warren and Katharine Schlinger Professor of Chemical Engineering
We have translated two nanoparticle-based therapeutics into the clinic for use as cancer therapeutics. These nanoarparticles have been investigated in 10 clinical trials. I will describe how we translated these nanoparticles from the laboratory at Caltech into clinical therapeutics. Lessons learned from these translational and clinical experiences are accelerating our current translational efforts with nanoparticle-based therapeutics for cancer. Additionally, we are in the process of creating nanoparticle-based therapeutics for treating diseases of the kidney and for crossing the blood brain barrier to provide therapeutics for treating maladies in the brain.